Study: NMOSD Treated with Rituximab and Eculizumab Has Lower Risk of Relapse

A recent study has demonstrated that neuromyelitis optica spectrum disorder (NMSOD) patients treated with eculizumab have a lower risk of adjudicated relapse compared to those treated with placebo.

This study specifically examined this treatment in patients who had been treated with rituximab in the past.

PREVENT

A past trial, called PREVENT, demonstrated that NMSOD patients who were given eculizumab instead of a placebo had a lower risk of relapse.

In this investigation, 46 of the patients had been given rituximab in the past. However, this trial did not specifically investigate the safety or efficacy of eculizumab treatment in this patient population.

The new study aimed to evaluate this group of patients specifically.

The New Study

This study was a post-hoc analysis of the 46 aquaporin-4 immunoglobulin G-positive NMOSD patients who had participated in the PREVENT trial. This subgroup of patients had similar characteristics to the rest of the trial participants at baseline except that the subgroup had a smaller percentage of Asian patients and a larger proportion of individuals from North and South America.

All of the patients had been given rituximab within the past year. All of them had received the therapy more than 3 months before the PREVENT trial began.

Of the 46 individuals, 26 were a part of the eculizumab group and 20 were a part of the placebo group. The treatment group was given 1200mg of eculizumab every 2 weeks. The placebo group was also given placebo every 2 weeks.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email